Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
[18F]Fluorine-18 (radiolabel of fluorodeoxyglucose)
1L, 2L, 3L, 4LFirst-, second-, third-, and fourth-line therapy
2/3L, 2L/3L+Second- or third-line therapy; second-line or third-or-later-line therapy
4OH-tamoxifen4-Hydroxytamoxifen
AACActual acquisition cost
ABC, aBCAdvanced breast cancer
ABC88th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer
ADC, ADCsAntibody-drug conjugate
ADLTAdvanced Diagnostic Laboratory Test
ADPAdenosine diphosphate (in poly [ADP-ribose] polymerase)
AE, AEsAdverse event
AF, AF-1, AF-2, AF1, AF2Activation function; activation function 1 (N-terminal, ligand-independent) and 2 (C-terminal, ligand-dependent) domains of the estrogen receptor
AHFSAmerican Hospital Formulary Service
AI, AIsAromatase inhibitor
AKT, AKT1, AKT2, AKT3AKT serine/threonine kinase (protein kinase B) and its isoforms 1, 2, and 3
AKT1mutAKT1 mutation
ALTAlanine aminotransferase
A/MBCAdvanced or metastatic breast cancer
APAlkaline phosphatase (estrogenic agonist activity assay)
aRRAdjusted risk ratio
ASCOAmerican Society of Clinical Oncology
ASCO/CAP, ASCO-CAPAmerican Society of Clinical Oncology and College of American Pathologists
ASTAspartate aminotransferase
ASTROAmerican Society for Radiation Oncology
ATCAnatomical Therapeutic Chemical classification
AUCArea under the concentration-time curve
AUC0–24, AUC0-24, AUC0–24,ssArea under the concentration-time curve from time 0 to 24 hours (at steady state)
AWPAverage wholesale price
BCBreast cancer
BCRPBreast cancer resistance protein
BCSSBreast cancer-specific survival
BIABudget impact analysis
BICRBlinded independent central review
BIDTwice daily
BIRCBlinded independent review committee
BLBasal-like (intrinsic subtype)
BMBrain metastases
BMAsBone-modifying agents
BPBone pain
BRCA, BRCA1, BRCA2, BRCA1/2Breast cancer susceptibility gene (1 and 2)
BRCAm, gBRCAmBRCA-mutated; germline BRCA-mutated
C1, C1D1, C1D2, C1D15, C2D15, C3D1, C3D15, C5D1, C7D1, C9D1, D8, D15, D16Treatment cycle (C) and day (D); for example, C1D1 is cycle 1, day 1
CADTHCanadian Agency for Drugs and Technologies in Health
CAMA-1Estrogen receptor-positive, ESR1 wild-type human breast cancer cell line
Cavg, Cavg,ssAverage plasma concentration (at steady state)
CBRClinical benefit rate
CBRASClinical benefit rate analysis set
CDKCyclin-dependent kinase
CDK4, CDK4/6Cyclin-dependent kinase 4; cyclin-dependent kinases 4 and 6
CDK4/6i, CDK4/6isCyclin-dependent kinase 4 and 6 inhibitor
CDxCompanion diagnostic
CEHRTCertified electronic health record technology
CERAN, CERANsComplete estrogen receptor antagonist
cfDNACell-free deoxyribonucleic acid
CFRCode of Federal Regulations
CGPComprehensive genomic profiling
ChTChemotherapy
CI, CIsConfidence interval
CLIAClinical Laboratory Improvement Amendments
Cmax, Cmax,ssMaximum plasma concentration (at steady state)
Cmin, Cmin,ssMinimum plasma concentration (at steady state)
CMOsContract manufacturing organizations
CMSCenters for Medicare & Medicaid Services
CNSCentral nervous system
CoACoactivator
cPR, cPRsConfirmed partial response
CQIContinuous quality improvement
CQOLCCaregiver Quality of Life Index-Cancer
CRComplete response; credible range (cost model output)
CRBNCereblon
CSFCerebrospinal fluid
CTComputed tomography
CTCsCirculating tumor cells
ctDNACirculating tumor deoxyribonucleic acid
CtroughTrough plasma concentration
CYCalendar year
CYPCytochrome P450
CYP3A, CYP3A4, CYP3 A4Cytochrome P450 subfamily 3A; cytochrome P450 isoenzyme 3A4
Dato-DXdDatopotamab deruxtecan
DC50Concentration producing 50% of maximal degradation
DCISDuctal carcinoma in situ
ddPCRDroplet digital polymerase chain reaction
DFIDisease-free interval
DLT, DLTsDose-limiting toxicity
DNADeoxyribonucleic acid
dnMBCDe novo metastatic breast cancer
DOR, DoRDuration of response
DPYDDihydropyrimidine dehydrogenase gene
DSPDisease Specific Programme (Adelphi Real World survey)
DVTDeep vein thrombosis
E2Estradiol
E2FE2F transcription factor
E3E3 ubiquitin ligase
EAGExternal Assessment Group (NICE)
EBCEarly breast cancer
ECG, ECGsElectrocardiogram
ECOGEastern Cooperative Oncology Group
EDEmergency department
EFSEfficacy analysis set
EGFREpidermal growth factor receptor
EHRElectronic health record
ELAElacestrant
EMAEuropean Medicines Agency
EmaxMaximal effect (maximal degradation or inhibition)
EOLEnd of life
EOMEnhancing Oncology Model
EORTCEuropean Organisation for Research and Treatment of Cancer
ePROsElectronic patient-reported outcomes
EQ-5D-3L, EQ-5D-5L, EQ-5D-5 LEuroQol 5-dimension health status instrument (3-level and 5-level versions)
EREstrogen receptor
ER+Estrogen receptor-positive
ERα, ERa, ERalphaEstrogen receptor alpha
ERBB2Erb-b2 receptor tyrosine kinase 2 (gene encoding HER2)
ERKExtracellular signal-regulated kinase
ESCATESMO Scale for Clinical Actionability of molecular Targets
ESMOEuropean Society for Medical Oncology
ESMO-MCBSESMO Magnitude of Clinical Benefit Scale
ESR1, ESR-1Estrogen receptor 1 gene
ESR1m, ESR1mut, ESR1-mut, ESR1-MUT, mutESR1ESR1 mutation or ESR1-mutated
ESR1-mut-ndESR1 mutation not detected
ESR1-wt, ESR1-WTESR1 wild-type
ET, ETsEndocrine therapy
E.U., EUEuropean Union
EVEEverolimus
evLYGEqual value of life-years gained
EXEExemestane
FAFinal analysis
FACT-BFunctional Assessment of Cancer Therapy-Breast
FASFull analysis set
FAT1FAT atypical cadherin 1 gene
FDAFood and Drug Administration
FGFasting glucose
FGFR1Fibroblast growth factor receptor 1
FHRDFlatiron Health Research Database
FPGFasting plasma glucose
FTFinancial toxicity
FULFulvestrant
GAGenomic alteration
GeoCVGeometric coefficient of variation
GeoMeanGeometric mean
GHSGlobal health status
GHS/QoL, GHS/QOLGlobal health status/quality of life (EORTC QLQ-C30 scale)
GLOBOCANGlobal Cancer Observatory estimates of cancer incidence, mortality, and prevalence (International Agency for Research on Cancer)
GnRHGonadotropin-releasing hormone
GREB1Growth regulating estrogen receptor binding 1 gene
H12Helix 12 of the estrogen receptor ligand-binding domain
HDIHuman Development Index
HER2, HER-2Human epidermal growth factor receptor 2
HER2+Human epidermal growth factor receptor 2-positive
HER2/neuHuman epidermal growth factor receptor 2 (neu oncogene product)
hERGHuman ether-a-go-go-related gene (potassium channel)
HHNKSHyperglycemic hyperosmolar nonketotic syndrome
HICsHigh-income countries
HR, HRsHazard ratio; hormone receptor; heart rate
HR+, HR-Hormone receptor-positive, hormone receptor-negative
HRQoL, HRQOLHealth-related quality of life
HRSNHealth-related social needs
HTAHealth technology assessment
IC5050% inhibitory concentration
ICCInvestigator's choice of chemotherapy
ICER, ICERsIncremental cost-effectiveness ratio
ICHInternational Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
ICH E14ICH guideline E14 on clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential
ICURIncremental cost-utility ratio
IDIdentifier
IDMCIndependent data monitoring committee
IHCImmunohistochemistry
ILDInterstitial lung disease
IMIntramuscular
INNInternational nonproprietary name
IOMInstitute of Medicine
IPInpatient
IQRInterquartile range
ISIntrinsic subtype
ISHIn situ hybridization
ITCIndirect treatment comparison
ITTIntent to treat
JPYJapanese yen
Ki67Ki-67 nuclear proliferation antigen
KMKaplan-Meier
LABCLocally advanced breast cancer
LBDLigand-binding domain
LBxLiquid biopsy
LHRHLuteinizing hormone-releasing hormone
LMDLeptomeningeal disease
LMICsLow- and middle-income countries
M1Distant metastasis category of the TNM staging system
MAEsMajor adverse events
MAICMatching-adjusted indirect comparison
MAPKMitogen-activated protein kinase
MBC, mBCMetastatic breast cancer
MCF7Estrogen receptor-positive, ESR1 wild-type human breast cancer cell line (Michigan Cancer Foundation-7)
mCRCMetastatic colorectal cancer
MDMaryland
MEKMitogen-activated protein kinase kinase
MG-132Peptide aldehyde proteasome inhibitor (research compound)
MIPSMerit-based Incentive Payment System
mLCMetastatic lung cancer
mOSMedian overall survival
mPFSMedian progression-free survival
MRIMagnetic resonance imaging
MTDMaximum tolerated dose
mTORMechanistic target of rapamycin
mTORC1, mTORC2Mechanistic target of rapamycin complex 1 and complex 2
mTORiMechanistic target of rapamycin inhibitor
mTTNTMedian time to next treatment
NANot available (table values)
NCCNNational Comprehensive Cancer Network
NCINational Cancer Institute
NCI-CTCAENational Cancer Institute Common Terminology Criteria for Adverse Events
NCoR, NCoR1Nuclear receptor corepressor (1)
NCTNational Clinical Trial (ClinicalTrials.gov identifier)
NDA, NDAsNew Drug Application
NDCNational Drug Code
NENot estimable
NEOLNon-end of life
NGSNext-generation sequencing
NHSNational Health Service (England)
NICENational Institute for Health and Care Excellence
NR3A1Nuclear receptor subfamily 3, group A, member 1 (estrogen receptor alpha)
OCMOncology Care Model
ONSOncology Nursing Society
OPOutpatient
OP-1250Olema Oncology development code for palazestrant
OP-3136Olema Oncology development code for an investigational lysine acetyltransferase 6 (KAT6) inhibitor
ORRObjective response rate; overall response rate
OSOverall survival
OWSAOne-way sensitivity analysis
PALB2Partner and localizer of BRCA2 gene
PARPPoly(adenosine diphosphate-ribose) polymerase
PARPiPoly(adenosine diphosphate-ribose) polymerase inhibitor
PBOPlacebo
PCRPolymerase chain reaction
PDPharmacodynamic
PD-1Programmed cell death protein 1
PD-L1Programmed death-ligand 1
PETPositron emission tomography
PFPathological fracture
PFSProgression-free survival
PFS2Progression-free survival on the next line of therapy
P-gpP-glycoprotein
PGR, PgRProgesterone receptor (gene)
PI3KPhosphatidylinositol 3-kinase
PI3Kα, PI3Ka, PI3K-alphaPhosphatidylinositol 3-kinase alpha
PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene
PIK3CAmutPIK3CA mutation
PKPharmacokinetics
POOrally
PPP6 MPer patient per 6 months
PPPMPer patient per month
PR, PRsPartial response
PRAsParticipant redesign activities (Enhancing Oncology Model)
PRO, PROsPatient-reported outcome
PROTACProteolysis targeting chimera
PSAProbabilistic sensitivity analysis
PSMPartitioned survival model
PTEPatent term extension
PTENPhosphatase and tensin homolog gene
Q3, Q4Third and fourth quarter of the year
QALY, QALYsQuality-adjusted life year
QDOnce daily
QLQ-BR23EORTC Quality of Life Questionnaire breast cancer module (23 items)
QLQ-C30EORTC Quality of Life Questionnaire Core 30
QoLQuality of life
QTQT interval
QTcQT interval corrected for heart rate
QTcFQT interval corrected using the Fridericia method
R2PD, RP2DRecommended phase 2 dose
RAFRapidly accelerated fibrosarcoma kinase
RANKReceptor activator of nuclear factor kappa B
RASRat sarcoma GTPase
RB, RB1Retinoblastoma protein; retinoblastoma 1 gene
RECISTResponse Evaluation Criteria in Solid Tumors
REMSRisk Evaluation and Mitigation Strategy
rMBCRecurrent metastatic breast cancer
RRRelative risk (rate ratio)
RTRadiation therapy
RTKsReceptor tyrosine kinases
rwOSReal-world overall survival
rwPFS, rwPFS-2L, rwPFS-3LReal-world progression-free survival (in second-line and third-line therapy)
SABCSSan Antonio Breast Cancer Symposium
SAE, SAEsSerious adverse event
SAFSafety analysis set
SCCSpinal cord compression
SDStable disease; standard deviation
SEStandard error
SEERSurveillance, Epidemiology, and End Results program
SERCAsSelective estrogen receptor covalent antagonists
SERD, SERDsSelective estrogen receptor degrader
SERM, SERMsSelective estrogen receptor modulator
SGSacituzumab govitecan
sIPTWStabilized inverse probability of treatment weighting
SNVsSingle nucleotide variants
SOCStandard of care
SRE, SREsSkeletal-related event
ssSteady state (subscript in pharmacokinetic parameters)
SSOSociety of Surgical Oncology
ST941CESR1-mutant breast cancer cell line derived from the ST941 patient-derived xenograft model
T1, T2Primary tumor size categories 1 and 2 of the TNM staging system
t1/2, T1/2Elimination half-life
t1/2effEffective half-life
T1N0, T1N1–3, T1N4–9, T2N0, T2N1–3, T2N4–9Primary tumor category 1 or 2 with no, 1 to 3, or 4 to 9 involved axillary lymph nodes
TB01TROPION-Breast01 trial
TBxTissue biopsy
T-DXdTrastuzumab deruxtecan
TEAE, TEAEsTreatment-emergent adverse event
TFTumor fraction (of circulating cell-free DNA)
TIHTumor-induced hypercalcemia
Tmax, tmax, Tmax,ssTime to maximum plasma concentration (at steady state)
TNBCTriple-negative breast cancer
TPCTreatment of physician's choice
TRAE, TRAEsTreatment-related adverse event
Trop-2Trophoblast cell-surface antigen 2
TTDTime to deterioration
TTNTTime to next treatment
TTOTime trade-off
TTPTime to progression
UKUnited Kingdom
ULNUpper limit of normal
uPR, uPRsUnconfirmed partial response
US, U.S., USAUnited States
UWWUterine wet weight
VCVisceral crisis
VMSVasomotor symptoms
WACWholesale acquisition cost
WBCWhite blood cell (count)
WHOWorld Health Organization
WPWork productivity
WTWild-type
WTPWillingness to pay